Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma

Abstract

Introduction Brentuximab vedotin (Bv) has been approved for the treatment of Refractory/Relapsed (R/R) Anaplastic Large Cell Lymphomas (ALCL) and cutaneous T-Cell Lymphomas, but is also effective in other CD30+ malignancies. We report here the outcomes of patients with various R/R Peripheral T Cell Lymphoma (PTCL) treated with Bv in real life practice. Method This was a retrospective, single-center study based on medical records of patients with R/R PTCL treated either with Bv alone or in combination with chemotherapy. Results Among 27 patients treated with Bv, neutropenia was the main serious adverse event observed in particular when Bv was used as combination treatment. The complete Response Rates (CRR) was 40.7%; it was significantly improved when Bv was used as combination treatment. The majority of eligible patients (7/10) underwent Stem Cell Transplantation. Median Progression Free Survival (PFS) and Overall Survival (OS) were 5.2 months and 12.5 months respectively. Conclusion Our current study shows that Bv used in combination with chemotherapy provides a high CRR and thereby allows SCT in R/R PTCL. The use of Bv treatments in this setting warrants further investigation.

Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives

“…However, several analyses have assessed brentuximab vedotin in patients with PTCL in real-life settings. In a single-center study of 27 patients with refractory/relapsed PTCL treated with brentuximab vedotin in a real-life practice, ORR was 63.0%, and after a median follow-up of 12.5 months, median PFS and OS were 5.2 and 12.5 months, respectively [ 80 ]. Response rates were improved when brentuximab vedotin was used in combination with chemotherapy compared with brentuximab vedotin monotherapy [ 80 ].…”

“…In a single-center study of 27 patients with refractory/relapsed PTCL treated with brentuximab vedotin in a real-life practice, ORR was 63.0%, and after a median follow-up of 12.5 months, median PFS and OS were 5.2 and 12.5 months, respectively [ 80 ]. Response rates were improved when brentuximab vedotin was used in combination with chemotherapy compared with brentuximab vedotin monotherapy [ 80 ]. In 101 patients with sALCL in Japan, brentuximab vedotin treatment led to a 1-year OS of 79.3% and an ORR of 62.0% [ 55 ].…”

Case Report: A recurrent case of ALK-ALCL after autologous transplantation was successfully treated with BV + a modified CHEP chemotherapy containing mitoxantrone hydrochloride liposome with the addition of chidamide maintenance therapy

“…Molecular targeted agents, including brentuximab vedotin (BV) and histone deacetylase inhibitors (romidepsin and chidamide), hold some promise for R/R ALK-ALCL. BV was approved for R/R ATCL in 2011 and is increasingly being used to induce remission in relapsed patients (13)(14)(15). Romidepsin is recommended in treatment for relapsed or refractory peripheral and cutaneous Tcell lymphoma (16, 17).…”